Ann: Shareholder Letter Reports Pipeline Advances and Milestones, page-14

There are 6 things I like about ATH and I have a 1 to 2 year outlook for share price as the asset is further derisked with phase 2 trials.

1. It is targeting what they believe is the cause and not just treating symptoms.
2. The drug is an oral dose that crosses the blood brain barrier.
3. It has orphan drug designation for MSA in Europe and America which provides exclusive market for 7 to 10 years.
4. The build up of iron in the brain is also considered to be a factor in alzheimers.
5. Some in human phase 2 data will start coming out around mid year.
6. Although there is still development risk the share price is very undervalued in my opinion given the risk versus reward.

If you are not familiar with neuroscience and neurological disorder treatment these links might help to understand the importance of crossing the blood brain barrier. Being able to deliver the drug to where it is needed in the required quantity is an important piece of the puzzle.

What is the blood brain barrier….

Treatment of Alzheimer’s Disease and Blood Brain Barrier Drug Delivery.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697739/